Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in life sciences, reported higher revenues and adjusted earnings for the fourth quarter of fiscal 2025. The numbers also surpassed estimates. The stock declined early Thursday after the management issued cautious guidance.
Fourth-quarter revenue increased to $12.2 billion from $11.4 billion in the comparable quarter of 2024. Organic revenue growth was 3%. The top-line exceeded Wall Street’s estimates.
Earnings, on an adjusted basis, rose 8% year-over-year to $6.57 per share. Net income, on a reported basis, was $1.96 billion or $5.21 per share in the December quarter, compared to $1.83 billion or $4.78 per share a year earlier.
In the post-earnings conference call, management said it expects organic revenue growth for Q1 FY26 to be a couple of points below the full-year pace and earnings growth to be in low-single-digit. It forecasts full-year revenue in the range of $46.3 billion to $47.2 billion and adjusted earnings per share between $24.22 and $24.8. The earnings forecast is below analysts’ latest estimates.
“Throughout the year, we effectively navigated the external environment and leveraged our PPI Business System to enable excellent operational performance. It was also a very active year for capital deployment, as we advanced our strategy and added exciting new capabilities that further strengthen our long-term competitive position,” said Marc Casper, chief executive officer of Thermo Fisher Scientific.